CBIO
CRESCENT BIOPHARMA, INC.
Last earnings -12.6% on 2026-04-29
$18.56
▲ +9.24%$18.56▲ +21.31%
over 1Y
L $8.94EODHDH $26.98
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+9.2%
1W+5.6%
1M-10.7%
3M+22.4%
YTD+67.5%
1Y+21.3%
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 15 analysts
Strong Buy
Conservative balance sheet (liabilities/equity 0.18x); but unprofitable (net margin -1419.6%).
Revenue (FY2025) $10.8M · FY2025
CRESCENT BIOPHARMA, INC. shows $10.8M in FY2025 revenue, a -1419.6% net margin, and -75.8% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | $10.8M |
| Gross profit | — | — | — | — | — |
| Operating income | -$63.4M | -$47.4M | -$39.3M | -$40.0M | -$153M |
| Net income | -$63.4M | -$46.7M | -$36.9M | -$37.9M | -$154M |
| Diluted EPS | -$1.23 | -$0.89 | -$0.58 | -$0.59 | — |
| Net margin | — | — | — | — | -1419.6% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$298M
EV / EBITDA—
EV / Sales27.5
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-30.1%
FCF yield-14.2%
Quality & risk
ROIC (est.)-59.4%
Free cash flow-$72.5M
Total debt—
Net cash$213M
Altman Z-Score6.18 safe
Piotroski F-Score4/6
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY-57.3%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRed flag in recent filings — restated periodic report (2026-06-22). Worth a closer look.
Recent filings
all on EDGAR ↗4Period ending 2026-06-222026-06-23open ↗4Period ending 2026-06-222026-06-23open ↗4Period ending 2026-06-222026-06-23open ↗4Period ending 2026-06-222026-06-23open ↗4Period ending 2026-06-222026-06-23open ↗4Period ending 2026-06-222026-06-23open ↗4Period ending 2026-06-222026-06-23open ↗424B3Filing2026-06-22open ↗10-Q/APeriod ending 2026-03-312026-06-22open ↗4Period ending 2026-06-022026-06-03open ↗4Period ending 2026-06-022026-06-03open ↗4Period ending 2026-06-022026-06-03open ↗
Frequently asked
- Is CRESCENT BIOPHARMA, INC. (CBIO) a buy?
- CBIO currently carries a Sell rating with 3/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.18x); but unprofitable (net margin -1419.6%).
- What is CRESCENT BIOPHARMA, INC.'s quality score?
- CBIO scores 31/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001253689, latest 10-Q filed 2026-04-29) · EODHD · as of 6/26/2026, 7:28:29 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.